AstraZeneca plc (LON:AZN) Given Average Recommendation of “Hold” by Brokerages

Shares of AstraZeneca plc (LON:AZN) have received an average rating of “Hold” from the nineteen analysts that are currently covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is GBX 6,592.86 ($86.15).

A number of brokerages have recently weighed in on AZN. Liberum Capital restated a “hold” rating on shares of AstraZeneca in a research report on Friday, March 29th. UBS Group restated a “sell” rating on shares of AstraZeneca in a research report on Thursday, June 20th. Deutsche Bank set a GBX 6,800 ($88.85) price target on shares of AstraZeneca and gave the company a “buy” rating in a report on Monday. Jefferies Financial Group reaffirmed a “hold” rating on shares of AstraZeneca in a report on Thursday, March 14th. Finally, Goldman Sachs Group reaffirmed a “sell” rating on shares of AstraZeneca in a report on Monday, March 18th.

In other news, insider Marc Dunoyer acquired 8,500 shares of the firm’s stock in a transaction on Tuesday, May 7th. The stock was acquired at an average price of GBX 5,800 ($75.79) per share, with a total value of £493,000 ($644,191.82). Also, insider Philip A. J. Broadley acquired 520 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was purchased at an average cost of GBX 5,738 ($74.98) per share, with a total value of £29,837.60 ($38,988.11).



Shares of AstraZeneca stock traded down GBX 77 ($1.01) during trading on Friday, reaching GBX 6,365 ($83.17). 1,166,979 shares of the stock traded hands, compared to its average volume of 2,310,000. The firm has a market cap of $83.49 billion and a P/E ratio of 33.50. The firm’s fifty day moving average price is GBX 6,027.76. The company has a debt-to-equity ratio of 179.66, a current ratio of 0.75 and a quick ratio of 0.57. AstraZeneca has a 52-week low of GBX 5,110 ($66.77) and a 52-week high of GBX 6,545 ($85.52).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Story: Average Daily Trade Volume – What It Means In Stock Trading

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.